Human mesenchymal stem cells and their use in cell‐based therapies
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
The human population is increasingly facing various diseases, including types of cancer, that cannot be cured with conventional drugs. Advanced drug targeting of tumor cells is also often impossible when treating highly invasive and infiltrative tumors such as glioblastoma or pulmonary cancer, because of tumor cells' high migration and invasiveness. Pluripotent human mesenchymal stem cells (hMSCs) have been extensively studied, and strategies are being proposed for treating “incurable” cancers and injury/disease‐affected organs. Because of their own intrinsic properties, involving homing and immunomodulatory potency, hMSCs could be used as an excellent cell/drug delivery vehicle in those cell‐based therapies. Their unprecedented use has been shadowed, however, by their spontaneous transformation, which links them to cancer‐initiating cells during tumor development. How malignant initiation proceeds in vivo, and what are the exact characteristics of the cancer‐initiating cells, still remain to be investigated. In the present review, the authors summed up the most recent knowledge about hMSC characteristics, their malignant transformation, and outlined the possibilities of their safe use in novel cell‐based therapies. Cancer 2010. © 2010 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Human mesenchymal stem cells modulate allogeneic immune cell responses
Aggarwal, S., & Pittenger, M. F. (2005) · Blood · doi:10.1182/blood-2004-04-1559 · Cited by 4,511
Kern, S., Eichler, H., Stoeve, J., Klüter, H., & Bieback, K. (2006) · STEM CELLS · doi:10.1634/stemcells.2005-0342 · Cited by 3,370 · cited 1×
“With 100% efficiency they can be isolated from bone marrow (BM) aspirates, adipose tissues, and umbilical cords,(5) whereas from fresh cord blood the isolation efficiency is only 30%(5) to 63%.(6,7) The lowest 19.”
BackgroundLe Blanc, K., Rasmusson, I., Sundberg, B., Götherström, C., Hassan, M., Uzunel, M., & Ringdén, O. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16104-7 · Cited by 2,734
Horwitz, E. M., Gordon, P. L., Koo, W. K. K., Marx, J. C., Neel, M. D., McNall, R. Y., Muul, L., & Hofmann, T. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.132252399 · Cited by 1,650
Isolation of multipotent mesenchymal stem cells from umbilical cord blood
Lee, O. K., Kuo, T. K., Chen, W.-M., Lee, K.-D., Hsieh, S.-L., & Chen, T.-H. (2004) · Blood · doi:10.1182/blood-2003-05-1670 · Cited by 1,360
Stolzing, A., Jones, E., McGonagle, D., & Scutt, A. (2008) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2007.12.002 · Cited by 1,195 · cited 2×
“By using a wide range of donor ages, measuring various hMSC parameters, a significant reduction of hMSCs’ fitness in adulthood relative to childhood was confirmed.(76) hMSCs undergo a decline in cell numbers, differentiation, and expansion capacity during aging.”
BackgroundHypoxia enhances proliferation and tissue formation of human mesenchymal stem cells
Grayson, W. L., Zhao, F., Bunnell, B., & Ma, T. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.05.054 · Cited by 521
Rebelatto, C. K., Aguiar, A. M., Moretão, M. P., Senegaglia, A. C., Hansen, P., Barchiki, F., Oliveira, J., Martins, J., Kuligovski, C., Mansur, F., et al. (2008) · Experimental Biology and Medicine · doi:10.3181/0712-rm-356 · Cited by 429
Cited by
Hackenberg, S., Scherzed, A., Kessler, M., Hummel, S., Technau, A., Froelich, K., Ginzkey, C., Koehler, C., Hagen, R., & Kleinsasser, N. (2011) · Toxicology Letters · doi:10.1016/j.toxlet.2010.12.001 · Cited by 473
Perico, N., Casiraghi, F., Introna, M., Gotti, E., Todeschini, M., Cavinato, R. A., Capelli, C., Rambaldi, A., Cassis, P., Rizzo, P., et al. (2011) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.04950610 · Cited by 297
Potential implications of mesenchymal stem cells in cancer therapy
Dai, L.-J., Moniri, M. R., Zeng, Z.-R., Zhou, J. X., Rayat, J., & Warnock, G. L. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.02.012 · Cited by 99
Mesenchymal stem cells and cancer: Friends or enemies?
Hong, I.-S., Lee, H.-Y., & Kang, K.-S. (2014) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/j.mrfmmm.2014.01.006 · Cited by 82
NguyenThai, Q., Sharma, N., Luong, D. H., Sodhi, S. S., Kim, J., Kim, N., Oh, S., & Jeong, D. K. (2015) · The Journal of Gene Medicine · doi:10.1002/jgm.2826 · Cited by 28
Metadata
- Authors
- Motaln, H., Schichor, C., & Lah, T. T.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2010-03-18
- Volume
- 116
- Issue
- 11
- Pages
- 2519-2530
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W2088413704
- Cited by
- 129
- References
- 8
- FWCI
- 7.78
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.